Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

September 4, 2021

Study Completion Date

September 4, 2021

Conditions
Poor Ovarian Reserve
Interventions
BIOLOGICAL

Autologous ovarian PRP injection

The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.

Trial Locations (1)

1373

Nadezhda Women's Health Hospital, Sofia

All Listed Sponsors
lead

Nadezhda Women's Health Hospital

OTHER

NCT04797377 - Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response | Biotech Hunter | Biotech Hunter